DAPAGLIFLOZIN 10mg. IP

The newest class of antihyperglycemic medications. (Plosker, 2012) A highly potent drug that reduces hyperglycemia by increasing urinary glucose excretion. (M Nauck, 2013) A beneficial therapeutic therapy for patients with type 2 diabetes and improves postprandial blood glucose. (Plosker, 2012) An effective drug in individuals both early and late in the course of diabetes. (Anders, 2014) Ameliorates glycemic control, reduces weight and fat mass, without affecting bone mineral density in type 2 diabetes subjects inadequately controlled on metformin. (J Bolinder, 2014) Improves glycemic parameters in patients with type 2 diabetes when used as monotherapy or in combination with metformin, glimepiride, pioglitazone, sitagliptin, or insulin. (Vivian, 2015) Represents a novel approach to the management of type 2 diabetes mellitus. (Niren K Shah, 2012) Significantly increases urinary glucose excretion and decreases glucose concentration in the bloodstream. (Theodosios D. Filippatos, 2015) Possesses blood pressure-lowering properties and leads to improvement in HbA1C measurements.(Michael A Weber, 2016) Reduces weight and produces less hypoglycemia than glipizide in type 2 diabetes patients who are inadequately controlled with metformin. (M Nauck, 2013) A well-tolerated medicine associated with sustained glycemic efficacy and greater reductions in body weight and systolic blood pressure than glipizide. (S Del Prato, 2015) A safe and effective drug as monotherapy or as an add-on to insulin or oral antidiabetic agents in type 2 diabetes patients. (Paola Fioretto, 2015)